Abstract | OBJECTIVES: METHODS: Study was performed using lung fibroblasts (LF) isolated from five patients with SSc-ILD and from three control subjects. RESULTS:
Nintedanib inhibited LF proliferation and migration in a concentration- and time-dependent manner. The proliferation rate of LF stimulated with PDGF in the presence of nintedanib was reduced 1.9-fold within 24 h as compared to cells stimulated with PDGF alone. Migration of SSc-ILD LF incubated with 100 nM nintedanib was reduced from 62.8±12.5% to 39.1±9.0% in the presence of PDGF and from 38.2±7.9% to 26.6±7.2% in serum-free medium. Nintedanib attenuated PDGF-induced Ca2+ efflux, reduced α-SMA promoter activity and α-SMA protein expression. Furthermore, nintedanib blocked PDGF-induced differentiation of normal LF to myofibroblasts, reduced production of collagen and fibronectin, and decreased contractility of SSc-ILD LF in both floating and fixed collagen gels. CONCLUSIONS: Our data demonstrate significant antifibrotic efficacy of nintedanib in SSc-ILD LF suggesting that nintedanib has the potential not only to prevent but also to reverse the increased activity of LF consequently attenuating excessive lung fibrosis observed in SSc-ILD.
|
Authors | Ilia Atanelishvili, Tanjina Akter, Atsushi Noguchi, Olha Vuyiv, Lutz Wollin, Richard M Silver, Galina S Bogatkevich |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2019 Jul-Aug
Vol. 37 Suppl 119
Issue 4
Pg. 115-124
ISSN: 0392-856X [Print] Italy |
PMID | 31573469
(Publication Type: Journal Article)
|
Chemical References |
- Indoles
- Protein Kinase Inhibitors
- nintedanib
|
Topics |
- Cells, Cultured
- Fibroblasts
(drug effects)
- Humans
- Idiopathic Pulmonary Fibrosis
(drug therapy, etiology)
- Indoles
(therapeutic use)
- Lung
(cytology)
- Lung Diseases, Interstitial
(drug therapy, etiology)
- Protein Kinase Inhibitors
(therapeutic use)
- Scleroderma, Systemic
(complications)
|